• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cost Analysis of Intravitreal Aflibercept vs Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy.增生型糖尿病视网膜病变玻璃体积血行玻璃体切割联合全视网膜光凝与玻璃体腔内注射阿柏西普的成本分析。
JAMA Ophthalmol. 2021 Jul 1;139(7):804-805. doi: 10.1001/jamaophthalmol.2021.1565.
2
Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.玻璃体积血患者增生性糖尿病视网膜病变中玻璃体内注射阿柏西普与全视网膜光凝联合玻璃体切除术对视力的影响：一项随机临床试验。
JAMA. 2020 Dec 15;324(23):2383-2395. doi: 10.1001/jama.2020.23027.
3
Infographic: intravitreous aflibercept vs vitrectomy with panretinal photocoagulation for vitreous haemorrhage from proliferative diabetic retinopathy.信息图：玻璃体内注射阿柏西普与玻璃体切割联合全视网膜光凝治疗增殖性糖尿病视网膜病变所致玻璃体积血的对比
Eye (Lond). 2022 Jan;36(1):8-9. doi: 10.1038/s41433-021-01530-0. Epub 2021 May 26.
4
Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.视力、玻璃体积血及其他眼部结局：玻璃体切割术与阿柏西普治疗糖尿病视网膜病变玻璃体积血的比较：一项随机临床试验的二次分析。
JAMA Ophthalmol. 2021 Jul 1;139(7):725-733. doi: 10.1001/jamaophthalmol.2021.1110.
5
Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.玻璃体内注射阿柏西普联合全视网膜光凝与早期玻璃体切除术治疗糖尿病性玻璃体积血：随机临床试验。
BMC Ophthalmol. 2020 Apr 6;20(1):130. doi: 10.1186/s12886-020-01401-4.
6
Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.阿柏西普单药治疗增生性糖尿病视网膜病变相关玻璃体积血的无内激光玻璃体切除术
Ophthalmic Surg Lasers Imaging Retina. 2023 Oct;54(10):609-610. doi: 10.3928/23258160-20230728-02. Epub 2023 Oct 1.
7
Anti-VEGF Therapy or Vitrectomy Surgery for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy.抗血管内皮生长因子治疗或玻璃体切除术治疗增殖性糖尿病视网膜病变所致玻璃体积血
JAMA. 2020 Dec 15;324(23):2375-2377. doi: 10.1001/jama.2020.22829.
8
Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.无内激光玻璃体切除术联合阿柏西普单药治疗增生性糖尿病视网膜病变相关玻璃体积血的并发症、依从性和 3 年结局。
Ophthalmic Surg Lasers Imaging Retina. 2023 Feb;54(2):89-96. doi: 10.3928/23258160-20221216-02. Epub 2023 Feb 1.
9
Reply to Letter to the Editor: Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.致编辑的信的回复：阿柏西普单药治疗增生性糖尿病视网膜病变相关玻璃体积血的无内激光玻璃体切除术
Ophthalmic Surg Lasers Imaging Retina. 2023 Oct;54(10):610-611. doi: 10.3928/23258160-20230827-01. Epub 2023 Oct 1.
10
Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).增生性糖尿病视网膜病变所致玻璃体出血治疗后活动障碍和工作生产力的变化：一项随机对照试验（DRCR 视网膜网络协议 AB）的次要结局。
PLoS One. 2023 Nov 16;18(11):e0293543. doi: 10.1371/journal.pone.0293543. eCollection 2023.

增生型糖尿病视网膜病变玻璃体积血行玻璃体切割联合全视网膜光凝与玻璃体腔内注射阿柏西普的成本分析。

Cost Analysis of Intravitreal Aflibercept vs Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy.

机构信息

Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor.

出版信息

JAMA Ophthalmol. 2021 Jul 1;139(7):804-805. doi: 10.1001/jamaophthalmol.2021.1565.

DOI:10.1001/jamaophthalmol.2021.1565
PMID:34042958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8160925/
Abstract

This economic evaluation study compares the costs of intravitreal injections of aflibercept, 2 mg, vs pars plana vitrectomy plus panretinal photocoagulation for nonclearing vitreous hemorrhage secondary to proliferative diabetic retinopathy.

摘要

本经济评价研究比较了 2mg 阿柏西普玻璃体内注射与玻璃体切割术联合全视网膜光凝治疗增生性糖尿病视网膜病变所致玻璃体积血未吸收的成本。